News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|March 1, 2024

Strategies for AE Management with T-DXd in Breast Cancer

Author(s)Carey K. Anders, MD, Heather Moore, CPP, PharmD, Rani Bansal, MD

Heather Moore, CPP, PharmD, shares expert insights on managing T-DXd-related adverse effects, including prophylactic measures for nausea and strategies for monitoring and management of ILD.

Episodes in this series

A panel of 4 experts on breast cancer seated at a long table

EP. 1 Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

Susan Dent, MD, an expert on breast cancer

EP. 2 Approaches for 1L Therapy and Restaging in Triple-Positive mBC

A panel of 4 experts on breast cancer

EP. 3 The Role of Radiotherapy in HER2+ mBC

Susan Dent, MD, an expert on breast cancer

EP. 4 Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

Heather Moore, CPP, PharmD, an expert on breast cancer

EP. 5 Treatment Considerations and AE Management Strategies with HER2-Directed Therapies

Carey Anders, MD, an expert on breast cancer

EP. 6 Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

A panel of 4 experts on breast cancer

EP. 7 HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

Carey Anders, MD, an expert on breast cancer

EP. 8 BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

Heather Moore, CPP, PharmD, an expert on breast cancer

EP. 9 Strategies for AE Management with Tucatinib in Breast Cancer

A panel of 4 experts on breast cancer seated at a long table

EP. 10 D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine

Rani Bansal, MD, an expert on breast cancer

EP. 11 Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

A panel of 4 experts on breast cancer seated at a long table

EP. 12 Advancements in Treating Brain Metastases in HER2+ Breast Cancer

A panel of 4 experts on breast cancer seated at a long table

EP. 13 Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

A panel of 4 experts on breast cancer seated at a long table

EP. 14 Strategies for AE Management with T-DXd in Breast Cancer

A panel of 4 experts on breast cancer seated at a long table

EP. 15 Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer

Carey K. Anders, MD, an expert on breast cancer

EP. 16 Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

Carey Anders, MD, an expert on breast cancer

EP. 17 Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer

Carey Anders, MD, an expert on breast cancer

EP. 18 BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

Carey Anders, MD, an expert on breast cancer

EP. 19 Future Perspectives on HER2+ Breast Cancer Treatment

EP. 20 Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

EP. 20 Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Soumen Das, MS, FACS, discussed the BCRADS-2 study and its potential to transform early breast cancer detection in low- and middle-income countries.

Transforming Breast Cancer Detection in Low/Middle Income Countries

BySoumen Das, MS, FACS, MRCS, FRCS

January 23rd 2026

Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC

ByCancer Network Staff

January 22nd 2026

FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer

ByCancer Network Staff

January 20th 2026

T-DXd/Pertuzumab Earns Type II Application Validation in EU for HER2+ mBC

ByAriana Pelosci

January 19th 2026

NCCN Thermometer Detects High Psychological Distress in Breast Cancer

ByCancer Network Staff

January 19th 2026

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Misty D. Shields, MD, PhD; Horace Tang, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Erminia Massarelli, MD, PhD, MS; Parth Khade, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Misty D. Shields, MD, PhD; Chandler Park, MD, MSc, FACP

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Addressing Unmet Needs in HER2+ Metastatic BTC

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

2nd Annual Hawaii Cancer Conference

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

19th Annual New York GU Cancers Congress™

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Proactive Adverse Event Management for HER2+ BTC Treatments

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Trending on CancerNetwork

New CAR T-Cell Therapy Earns FDA Breakthrough Status in T-Cell Malignancies

Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma

FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer

FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals

Camrelizumab Combo Shows Sustained Benefit in Resectable NSCLC